BACKGROUND:Implantable cardioverter defibrillators (ICDs) improve survival and extend lives of patients with severe heart disease. OBJECTIVE: We sought to evaluate the impact of ICDs on health-related quality of life (HRQOL) during the first 3 years after implantation. SUBJECTS: A total of 1089 patients from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) were randomized to an ICD or medical treatment only. MEASURES: Health Utility Index (HUI3) at baseline, 3, 12, 24, and 36 months following randomization; survival data. RESEARCH DESIGN: We constructed mean profiles of HRQOL for living patients, estimated overall quality-adjusted life years (QALYs), separately by treatment arm, and calculated cumulative QALY gains/losses as the difference between the areas under the treatment specific HRQOL profiles. Multivariate fixed effect regression models were developed to impute the missing HRQOL data using baseline patient characteristics (age, gender, treatment, HUI3 score, diabetes, diuretics use, and NYHA class). Bootstrapped standard errors were calculated for the estimated differences in HRQOL gains/losses between treatment arms. Similarly, we performed subgroup analyses (by gender, age, and baseline NYHA class, blood urine nitrogen, ejection fraction, and QRS). RESULTS: There were no differences in QALYs loss for living patients by treatment group (-0.037, P = 0.64) or in overall QALYs loss by treatment group (0.043, P = 0.37) over 3 years. In subgroup analysis, female subjects demonstrated a trend towards greater survival benefit (0.298, P = 0.07) and overall QALYs (0.261, P = 0.14). CONCLUSIONS: Adverse effects of the ICD on HRQOL together with lower HRQOL among survivors may offset the 3-year survival benefits of ICDs.
RCT Entities:
BACKGROUND: Implantable cardioverter defibrillators (ICDs) improve survival and extend lives of patients with severe heart disease. OBJECTIVE: We sought to evaluate the impact of ICDs on health-related quality of life (HRQOL) during the first 3 years after implantation. SUBJECTS: A total of 1089 patients from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) were randomized to an ICD or medical treatment only. MEASURES: Health Utility Index (HUI3) at baseline, 3, 12, 24, and 36 months following randomization; survival data. RESEARCH DESIGN: We constructed mean profiles of HRQOL for living patients, estimated overall quality-adjusted life years (QALYs), separately by treatment arm, and calculated cumulative QALY gains/losses as the difference between the areas under the treatment specific HRQOL profiles. Multivariate fixed effect regression models were developed to impute the missing HRQOL data using baseline patient characteristics (age, gender, treatment, HUI3 score, diabetes, diuretics use, and NYHA class). Bootstrapped standard errors were calculated for the estimated differences in HRQOL gains/losses between treatment arms. Similarly, we performed subgroup analyses (by gender, age, and baseline NYHA class, blood urine nitrogen, ejection fraction, and QRS). RESULTS: There were no differences in QALYs loss for living patients by treatment group (-0.037, P = 0.64) or in overall QALYs loss by treatment group (0.043, P = 0.37) over 3 years. In subgroup analysis, female subjects demonstrated a trend towards greater survival benefit (0.298, P = 0.07) and overall QALYs (0.261, P = 0.14). CONCLUSIONS: Adverse effects of the ICD on HRQOL together with lower HRQOL among survivors may offset the 3-year survival benefits of ICDs.
Authors: Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell Journal: Circ Cardiovasc Qual Outcomes Date: 2015-06-02
Authors: Lidia García-Pérez; Pilar Pinilla-Domínguez; Antonio García-Quintana; Eduardo Caballero-Dorta; F Javier García-García; Renata Linertová; Iñaki Imaz-Iglesia Journal: Eur J Health Econ Date: 2014-10-17
Authors: Honey Thomas; Mark Lambert; Chris Plummer; Craig Runnett; Richard Thomson; Anne Marie Troy-Smith; Andrew J Turley Journal: Br J Cardiol Date: 2020-07-28
Authors: Katia Noyes; Ethan Corona; Peter Veazie; Andrew W Dick; Hongwei Zhao; Arthur J Moss Journal: Am J Cardiovasc Drugs Date: 2009 Impact factor: 3.571
Authors: Lieke M van den Heuvel; Tanya Sarina; Joanna Sweeting; Laura Yeates; Kezia Bates; Catherine Spinks; Catherine O'Donnell; Samuel F Sears; Kevin McGeechan; Christopher Semsarian; Jodie Ingles Journal: Heart Rhythm O2 Date: 2022-02-08